Moderate
Established
الوصف
Rosuvastatin increases warfarin plasma concentrations through inhibition of CYP2C9, potentially leading to supratherapeutic INR values.
الآلية
Rosuvastatin inhibits CYP2C9, the principal enzyme for S-warfarin metabolism, resulting in reduced clearance and elevated warfarin levels.
الأهمية السريرية
INR increases of approximately 10–20% have been observed in pharmacokinetic studies; clinically significant bleeding has been reported.
التدبير
Monitor INR when initiating or adjusting rosuvastatin dose; the FDA label specifically warns about this interaction.